This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Theravance Inc. (THRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance (
THRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.1%. By the end of trading, Theravance rose $2.45 (6.3%) to $41.19 on heavy volume. Throughout the day, 2,518,142 shares of Theravance exchanged hands as compared to its average daily volume of 894,900 shares. The stock ranged in a price between $38.50-$41.80 after having opened the day at $38.55 as compared to the previous trading day's close of $38.74. Other companies within the Health Care sector that increased today were:
GW Pharmaceuticals PLC ADR (
GWPH), up 53.2%,
Genvec (
GNVC), up 43.7%,
ERBA Diagnostics (
ERB), up 38.2% and
Aratana Therapeutics (
PETX), up 15.3%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.1 billion and is part of the drugs industry. Shares are up 69.9% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Theravance as a
sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk.